Taking account of these points, the Committee considers that the actual benefit of RASILEZ (aliskiren) : - is moderate in other patients, i.e. patients who are not controlled by the five classes of antihypertensives that have proven their efficacy in terms of morbidity and mortality (diuretics, CEI, ARB, calcium-channel blockers and beta blockers), used alone or in combination, and who are not being treated with another RAAS inhibitor (CEI or ARB).
Insufficient
- remains insufficient in hypertensive patients treated with a combination already containing an inhibitor of the renin-angiotensin-aldosterone system (CEI or ARB), including patients with diabetes or renal impairment,
Listen
